CRDO
Not exactly a ringing endorsement
Credo’s latest call got the kind of review nobody wants: Sell. The core gripe isn’t that revenue is dead — it’s that the quality of that growth is looking a little squishy, with margins sliding, expenses climbing, and too much business tied up in too few customers.
The growth story has a catch
On paper, the company still has the kind of AI-connectivity glow investors love. But the outlook is leaning hard on a rapid ramp in new optical products, and those are still in the early innings. Translation: the story is exciting, but the evidence file is thin.
And there’s competition lurking in the background. Marvell and others are circling the same space, which means Credo doesn’t get to just skate on momentum forever.
The stuff that makes investors squint
A few other details are doing their best impression of a red flag parade:
- insider selling
- about $88 million in stock-based compensation in Q1
- a balance sheet with nearly half goodwill
That combination tends to make investors ask the same annoying-but-important question: is this a real long-term compounding machine, or just a stock that looks great until you dig a little deeper?
Big picture
Credo still has a growth narrative, but this note says the market may be paying champagne prices for something that could turn out to be more sparkling water. If the new products ramp fast, the bulls get to keep dancing. If not, the valuation starts looking a lot less heroic.